CLINICAL SCIENCE DEPT- PROJECTS
ONGOING
| Name of Project | Objective(s) |
|---|---|
| A prospective study to evaluate the safety, effectiveness and impact of the RTS, S/ASO1E vaccine in young children in sub-
Saharan Africa. (EPI-MAL 003) |
|
| An epidemiology study to assess Plasmodium falciparum parasite
prevalence and malaria control measures in catchment areas of
two studies pre- and post-RTS, S/AS01E introduction (EPI-MAL-
002 and EPI-MAL-003) to assess, in field conditions, vaccine
benefit: risk in children in Sub-Saharan Africa.
(EPI-MAL 005) |
|
| Temporal Strain Structure and Responses to Interventions in a
High Endemicity Region of Plasmodium Falciparum.
MRS-CMRS (BONGO MALARIA) |
|
| “A parallel-group, Phase III, multi-stage, modified double-
blind, multi-armed study to assess the efficacy, safety, and
immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant
Protein Vaccines (monovalent and bivalent) for prevention
against COVID-19 in adults 18 years of age and older as a
primary series and open-label extension to assess
immunogenicity, safety, efficacy of a monovalent booster dose
of SARS-CoV2 Adjuvanted Recombinant Protein Vaccine”
(Sanofi VAT00008 Study) |
|
| A Phase 1 Randomized, Blinded, Placebo-Controlled, Dose-
Escalation and Dosing Regimen Selection Study to Evaluate the
Safety and Immunogenicity of rVSV Vectored Lassa Virus
Vaccine in Healthy Adults at Multiple Sites in West Africa.
(LASSA Fever study) |
|
| Integrating Point of Care Testing (POCT) Technology into
Primary Care Settings to Advance the Diagnosis of Care of
Children with Sickle Cell Disease.
(Sickle Cell Disease study) |
|
YET TO COMMENCE
| Name of Project | Objective(s) |
|---|---|
| (PLATINUM): A multi-part, multi-center PLATform study to assess the efficacy, safety, tolerability, and pharmacokinetics of anti-malarial agents administered as monotherapy and/or combination therapy in patients with uncomplicated plasmodium falciparum Malaria. (PLATINUM Study) |
|
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19. (Atea Study) |
|
| To evaluate the efficacy of bemnifosbuvir (BEM) compared with placebo in reducing all-cause hospitalization or all-cause death in COVID-19 outpatients receiving only supportive care. (KALUMA Study) |
|
| Phase III, randomized, observer-blind, placebo-controlled, multi-centre, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers. | |
| A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19. (ACTIV 2D STUDY) |
|